The Phase 3 clinical trial (NCT04513925) investigating atezolizumab in combination with tiragolumab compared with durvalumab for participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) reached its primary completion on 2025-05-27. This study evaluated the efficacy and safety of the combination therapy.
Background
Atezolizumab is being investigated for its role in treating non-small cell lung cancer (NSCLC). The current study specifically focuses on participants with locally advanced, unresectable Stage III NSCLC who have received prior concurrent platinum-based chemoradiotherapy.
Trial design
The study, identified as NCT04513925, is a Phase 3 trial. It enrolled 829 participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who had received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and had not experienced radiographic disease progression. The trial's purpose was to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab, comparing it against durvalumab.
What this means
The primary completion of this Phase 3 trial signifies that the main data collection period for the study's primary objectives has concluded. Researchers will now proceed with data analysis to determine the efficacy and safety profile of atezolizumab in combination with tiragolumab compared to durvalumab for this specific population of NSCLC patients. The results are anticipated to provide crucial insights into potential new treatment options for locally advanced, unresectable Stage III NSCLC.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT04513925, titled "A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)," was updated to reflect primary completion on 2025-05-27 on clinicaltrials.gov.